A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

August 12, 2019

Primary Completion Date

August 12, 2024

Study Completion Date

August 12, 2024

Conditions
Parkinson's Disease
Interventions
DRUG

BIIB094

Administered as specified in the treatment arm.

DRUG

Placebo

Administered as specified in the treatment arm.

Trial Locations (18)

5053

Neuro-SysMed Center, Bergen

7030

St. Olav University Hospital, Trondheim

19107

University of Pennsylvania, Philadelphia

28007

Hospital General Universitario Gregorio Marañón, Madrid

37920

Alliance for Multispecialty Research, Knoxville

44195

The Cleveland Clinic Foundation, Cleveland

48334

Quest Research Institute, Farmington Hills

48903

Laboratorios de Investigación Biocruces 3., Hospital de Cruces, Barakaldo

60611

Northwestern University PD and Movement Disorders Center, Chicago

64239

Sourasky Medical Center, Tel Aviv

97239

Oregon Health and Science University, Portland

99202

Inland Northwest Research, Spokane

Unknown

Research Site, Toronto

Research Site, Seville

QC H3A 2B4

Montreal Neurological Institute and Hospital, Montreal

08195

Hospital General de Catalunya, Barcelona

08036

Hospital Clinic de Barcelona, Barcelona

WC1N 3BG

Queen Square (Neurology) CRF Site Institute of Neurology & the National Hospital for Neurology and Neurosurgery UCLH, London

Sponsors
All Listed Sponsors
lead

Ionis Pharmaceuticals, Inc.

INDUSTRY